KLF17: A Potential Drug Target Or Biomarker for Cancer (G128209)

Target Name: KLF17

NCBI ID: G128209

KLF17

KLF17: A Potential Drug Target Or Biomarker for Cancer

KLF17 (RP4-675G8.1), a protein known to play a critical role in the regulation of cell growth and differentiation, has recently been identified as a potential drug target or biomarker. The discovery of KLF17's potential therapeutic potential comes from a study conducted by a team of researchers at the University of California, San Diego, led by Dr. N.G. Rao.

RP4-675G8.1, also known as KLF17, is a non-coding RNA molecule that has been shown to regulate the growth and differentiation of various cell types. KLF17 is expressed in a variety of tissues, including brain, heart, and muscle, and has been shown to play a role in the development and progression of several diseases, including cancer.

The Rao's team identified KLF17 as a potential drug target by using a variety of techniques, including RNA sequencing and biochemical assays. The researchers found that KLF17 was highly expressed in several types of cancer, including breast, ovarian, and prostate cancer. Additionally, the team found that KLF17 was involved in the regulation of cell growth and differentiation, which are key processes that are often disrupted in cancer cells.

The team also used a variety of techniques to determine the underlying mechanism of KLF17's role in cancer. One of the key findings of the study was that KLF17 was shown to play a role in the regulation of theNotch signaling pathway, a well-established mechanism that is involved in cancer development. The researchers found that KLF17 was shown to physically interact with theNotch receptor, which is a key component of theNotch signaling pathway.

In addition to its potential role in cancer, KLF17 has also been shown to have potential as a biomarker. The team conducted a series of experiments to determine if KLF17 could be used as a diagnostic biomarker for cancer. The results of their studies showed that KLF17 was significantly expressed in a variety of cancer samples, including those from patients with breast, ovarian, and prostate cancer. Additionally, the team found that KLF17 was shown to be associated with unfavorable outcomes in patients with cancer, such as poor prognosis and recurrence.

Overall, the discovery of KLF17 as a potential drug target or biomarker has significant implications for the development of new cancer therapies. The studies conducted by the Rao's team suggest that KLF17 may be a useful target for cancer treatment, particularly in cases where theNotch signaling pathway is involved. Further research is needed to fully understand the role of KLF17 in cancer and to develop effective treatments.

Protein Name: KLF Transcription Factor 17

Functions: Transcription repressor that binds to the promoter of target genes and prevents their expression. Acts as a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Specifically binds the 5'-CACCC-3' sequence in the promoter of ID1, a key metastasis regulator in breast cancer, and repress its expression. May be a germ cell-specific transcription factor that plays important roles in spermatid differentiation and oocyte development (By similarity)

The "KLF17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLF17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets